Radial adjustable multi-cartridge combination drug delivery device for hypodermic injection
By designing a multi-cartridge combination drug delivery device, the problems of complex formulation and medication errors in parenteral drug combination therapy are solved, and flexible dose timing and convenient delivery in non-clinical environments are achieved, which is suitable for the needs of complex combination therapy.
Patent Information
- Application Number
- CN202411106257.5
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2019-11-08
- Filing Date
- 2020-11-09
- Publication Date
- 2024-11-12
AI Technical Summary
The prior art has complexity in formulation and analysis, risk of medication errors, high patient burden, and supply chain management challenges in parenteral administration, especially when subcutaneous injection and intravenous infusion, making it difficult to achieve flexible dosing timing. and convenient delivery in non-clinical settings.
A multi-cartridge combination drug delivery device is designed, including a cylindrical box housing and a driving unit, which consists of two parts, with a plurality of cylindrical chambers for receiving the cartridge and passing through the hollow needle tip and fluid. The channel enables sequential delivery of drugs, and the drive unit includes a indexing device and a plunger drive device, which enables precise rotation and propulsion of the cartridge to ensure that the drug is delivered in the specified order and dose.
The device avoids the complexity of fixed-rate combination preparations, reduces the risk of medication errors, improves patient convenience, and achieves flexible dose timing and convenient delivery in non-clinical environments, suitable for the needs of complex combination therapies, including a variety of Use of drugs and active excipients.
Smart Images

Figure CN118924995A_ABST
Abstract
Description
[0001] This application is a divisional application of the Chinese patent application with application number 202080078068.5 (application date: November 9, 2020, invention name: radially adjustable multi-cartridge combination drug delivery device for subcutaneous injection). Technical Field
[0002] The field of the present invention is the subcutaneous administration of liquid drugs. More specifically, the present invention relates to the subcutaneous administration of two or more liquid drugs in combination in a fixed weight ratio. Background Art
[0003] Many drugs must be administered parenterally for a variety of reasons. For example, biotechnology-derived biopharmaceuticals are therapeutic proteins that cannot be delivered orally because they would be broken down by the digestive system, rendering them ineffective. Therefore, such biopharmaceuticals are typically delivered via administration routes that bypass the digestive system, most typically via intravenous and subcutaneous routes.
[0004] Recent advances in medicine, particularly in cancer treatment, have demonstrated that therapeutically beneficial effects can be achieved through synergistic combinations of two or more drugs.
[0005] For example, recent clinical studies have shown that the combination of anti-PD-1 checkpoint inhibitor drugs and CTLA4 checkpoint inhibitors can have a beneficial synergistic effect on some tumor types, which can lead to better clinical outcomes than can be achieved by administering either drug alone. Typically, such checkpoint inhibitor drugs are biotechnology-derived immunoglobulin-type monoclonal antibodies or fragments thereof. In some cases, it can be beneficial to use such biological drugs in combination with conventional chemotherapy drugs such as cytotoxic drugs.
[0006] There are several challenges in the co-administration of drugs parenterally, and various methods have been used to overcome them. These challenges include increased complexity of medication, greater risk of medication errors, and burden on patients. Greater complexity of medication can be manifested in a variety of ways, depending on the combination and the way the medication is administered. For example, one method of combining therapeutic biopharmaceuticals is by co-formulating them in a fixed ratio combination in a solution. This leads to the complexity of the formulation because a stable formulation needs to be ensured, in which the combined drugs maintain their efficacy and quality throughout the drug supply chain. Those of ordinary skill in the art will understand that such drug formulations typically will include several excipients, such as buffers, pH adjusters, tonicity adjusters, stabilizers, etc. As the number of combined drugs increases, the complexity of formulation also increases. Associated with the challenges of formulation are challenges associated with developing analytical methods for such complex formulations, such as assays to assess the quality, efficacy, and strength of each drug in the mixture. Another limitation of fixed ratio combinations is the loss of flexibility in the ratio of the drugs to be administered.
[0007] By compounding drugs from single-dose preparations closer to the point of care (e.g., in a compounding pharmacy), the complexity of preparation and analysis can be avoided and dosage flexibility can be maintained. In this case, a pharmacist or pharmacy technician follows the protocol of mixing individual drugs using aseptic techniques under a pharmacy hood. Most typically, this method is currently applied to mixing drugs in intravenous infusion bags, although the method can be applied in principle to be mixed into a vial for subsequent subcutaneous injection. Although the complexity of preparation and analysis is avoided by this method, complexity is transferred to the pharmacy. When this method is used to prepare intravenous infusion, it can only be carried out near the point of care of the patient who is visiting an infusion clinic. The advantages of the dosage and dosage ratio flexibility provided by this method have produced the risk of accompanying medication errors in the pharmacy, for example, by using incorrect drugs or mixing them with incorrect ratios. The inspection and control used in a well-organized pharmacy is designed to prevent such medication errors, but this risk provides another reason why this practice is limited to pharmacies near the point of care (such as in a hospital). A final risk of pharmacy compounding is the risk of exposure to medication or needle stick injury due to the multiple needle-based transfers that must be performed. This risk can be reduced by using compounding machines in the pharmacy, however such machines become another source of complexity and expense.
[0008] The complexity of formulation and analysis can also be avoided by administering the drugs separately (e.g., as separate intravenous infusions or subcutaneous injections). In some cases, this approach may be required for technical reasons, for example, if a stable fixed ratio formulation cannot be achieved. In the intravenous case, this approach provides only a slight reduction in protocol complexity for the pharmacy, which now needs to manage multiple compound infusions. This approach also does not eliminate the risk of medication errors. In both the intravenous and subcutaneous cases, the burden on patients is greater because they now have to endure multiple infusions or injections.
[0009] In some cases, for safety reasons, it is impossible to immediately administer all drugs. For example, the burden of excipients may be unacceptably high. In the case where biological drugs are derived from bacterial cell cultures, the residual bacterial endotoxin concentration, although controlled to the lowest possible level in downstream processing, may still prevent the immediate administration of multiple drugs in the combination. The need to manage excipients and endotoxin burdens may require patients to stay in the hospital for a few days or must visit a clinic within a few days, further increasing the burden on patients.
[0010] In principle, the medicine that is intended to be used for co-administered can be provided separately in a convenient pre-filled mode (such as pre-filled syringe, automatic syringe or body-worn syringe) for subcutaneous delivery, and is administered by the patient personally away from the clinical environment. This method can alleviate the needs of the patient to stay in the hospital or to visit the doctor multiple times, but this method will result in multiple injections, and therefore inconvenience and other accompanying safety risks, such as injection site reactions, are caused to the patient. This method has also produced a very large risk of medication error, because the patient must record their application status for each kind of medicine in the combination. If for safety or treatment reasons, for example, in order to manage endotoxin limits, the application time of the corresponding medicine is very important, so the risk of medication error caused by the incorrect timing of the composition dosage is also produced. By being packaged together with clear and definite instructions for use, the risk of medication error can be alleviated to a certain extent, but can not be completely eliminated.
[0011] Currently, for the reasons stated above, most parenterally administered drug combinations are administered via the intravenous route in the clinical setting.
[0012] For pharmaceutical companies that manufacture and distribute drugs as combination therapies, the co-formulation approach creates additional challenges and complexities in manufacturing and the supply chain. For companies with portfolios of individual drugs used in combination with each other, these complexities increase as the number of combinations offered increases.
[0013] Each new combination of drugs adds an additional single stock keeping unit (SKU) to the finished goods inventory. In addition, each new ratio or strength of the drug adds more SKUs. This rapid growth of SKUs is referred to in the supply chain management discipline as the "combination explosion." In accounting terms, the inventory of such SKUs is recorded as finished goods inventory. Additional complexity arises in the work-in-process (WIP) inventory because the individual drug substances or active pharmaceutical ingredients (API) must be stored in large quantities until compounded. Subsequently, large quantities of the compounded drug products must also be stored until filled into unit doses. In the case of biologic drugs, which are typically stored frozen at low temperatures, this leads to multiple freeze-thaw processes and the associated need for large refrigerated storage facilities and equipment.
[0014] Particularly when the drugs in question are expensive biologics, the financial impact of portfolio explosion and associated inventory growth can be significant, not only because of the working capital tied up as inventory, but also because of the expensive facilities required to store WIP and finished product inventory under refrigerated conditions.
[0015] Further challenges with co-formulated drug combinations arise in supply chain planning and forecasting due to the challenge of optimizing product mixes among the various possible combination SKUs in response to market demand. Because large quantities of API are stored "dispersed" among a potentially large number of finished product SKUs, accurate forecasting of demand is critical to minimizing the risk of over-inventorying some SKUs and under-inventorying others ("stock-outs"). For expensive biologic drugs, the costs associated with forecasting errors can be very large. This problem is further exacerbated because drugs are perishable commodities, meaning that unsold inventory can only be stored for a fixed period of time before it becomes obsolete. Obviously, such forecasting challenges increase with the number of drugs used in the combination and the SKUs in the product line.
[0016] In summary, for all the above reasons, it is necessary to solve the technology of each of these challenges associated with the delivery of combination therapy. The ideal technology will avoid the preparation and analysis complexity of fixed ratio combination preparations, avoid the combination explosion and inventory growth in manufacturing and supply chain, eliminate the risk of medication errors in pharmacies and care points (whether clinical or at home), and minimize the patient burden associated with multiple infusions or injections and dosage timing restrictions. The ideal technology should also maximize the convenience of the patient by enabling flexible and convenient delivery of combination therapy (e.g., in a home or other non-clinical environment). In order to maximize the convenience of the patient, the ideal technology should enable subcutaneous administration because it is more suitable for non-clinical environments. It should also foresee the progress of medicine, such as the development of more complex combination therapy, including three or more drugs and active excipients, such as hyaluronidase (e.g., recombinant human hyaluronidase, developed by Halozyme Therapeutics Inc in San Diego, California under the trade name Sale).
[0017] As another example of medical progress, recent advances in the science of immuno-oncology have shown that precise timing of the doses of the constituent drugs of combination therapies can have therapeutic benefits. For example, consider a combination therapy of "Drug A" and "Drug B", which is designed to target two biochemical targets "A" and "B" expressed by a specific tumor type, respectively. Recent developments have shown that in some cases, tumors may have time issues with their expression of targets, which may be affected by the timing of the administration of the corresponding drugs. For example, administering drug A that binds to target A at time zero may stimulate or upregulate the expression of target B at some time later (perhaps minutes, hours, or even days). In this case, it may be optimal to administer drug B when peak expression of target B occurs. This time-resolved dosing may be optimal for safety (e.g., reducing the dose of drug required for an equivalent therapeutic effect), efficacy, or both.
[0018] Given the biological nature of such time-resolved effects, they may be incompatible with conventional clinical schedules, and therefore to exploit them would require infusions at unconventionally scheduled clinical visits, increasing the clinical and patient burden of treatment. Therefore, to fully exploit these effects, subcutaneous delivery in a nonclinical setting is required to maximize flexibility in dose timing.
[0019] Therefore, the above-described ideal technology that enables subcutaneous infusion is also suitable for time-resolved dosing of therapeutic combinations.
[0020] Applicant has now recognized that the combined principles described in applicant's co-pending applications: U.S. Provisional Patent Application No. 62 / 670,266, PCT Application No. PCT / US2019 / 031727, PCT Application No. PCT / 2019 / 031762, and PCT Application No. PCT / US2019 / 031791 (which applications are incorporated herein by reference in their entirety), when implemented in a subcutaneous delivery device, can achieve the requirements of the above-mentioned ideal technology. Summary of the invention
[0021] In a first aspect of the present invention, a cartridge housing is provided, the cartridge housing being made of two parts of a generally cylindrical shape, defining a plurality of cylindrical chambers radially arranged around the circumference of the cylinder, the axis of each chamber being parallel to the axis of the cartridge housing, for receiving a cartridge filled with a liquid drug. The cartridge housing further comprises a central aperture, the central aperture being parallel to the cartridge axis for receiving the central spindle of a drive unit. The first part of the cartridge housing defines the distal end of the cartridge chamber. The distal end of the first part comprises a circular hole centered on the axis of each chamber, thereby providing an entrance to the distal end of the mounted cartridge for the plunger rod of the drive unit. The radius of the hole is less than the chamber diameter, approximating the inner diameter of the cartridge to be mounted in the chamber, so that when a force is applied backward to the cartridge, the hole also provides a bearing surface for the distal end of the cartridge. In an embodiment, the outer shape of the cartridge housing may partially deviate from the cylindrical shape to define an eccentricity, which may be used for alignment purposes when mounted in a drive unit, provided that the chamber remains radially arranged on a circle centered on the central axis of the cartridge housing.
[0022] The second portion of the cartridge housing defines the proximal end of each cartridge chamber and has a shape and size designed to fit to the first portion in a tight locking engagement to form a cartridge housing assembly. Thus, any eccentricity defined by the first portion is reflected by the design of the second portion. The proximal end of the second portion includes a circular hole at the proximal end of each cartridge chamber, the diameter of the circular hole being less than the outer diameter of the crimp seal of the cartridge to be installed, but greater than the diameter of the diaphragm of the cartridge, so as to define a bearing surface for retaining the cartridge in the chamber when a force is applied forwardly to the cartridge, while also exposing the rubber diaphragm of each cartridge filled with drug so as to be accessible from the exterior of the cartridge housing.
[0023] A box cap (also referred to herein as "box manifold top" and "manifold top") is further provided, the box cap comprising a plurality of hollow needle tips, the plurality of hollow needle tips being equal in number to the chambers of the box housing and being radially arranged on a circle, the circle being centered on the center of the box cap and having the same radius as the corresponding circle where the chambers of the box housing are arranged. The box cap is shaped to be closely matched with the box housing by a mating feature, the mating feature being designed to be locked and engaged with the corresponding mating feature on the box housing. In an embodiment in which the eccentricity is built into the box housing, this feature will also be present on the box cap to ensure the correspondence of the matching. Each hollow needle tip of the box cap is angularly distributed around the circle with the same pitch as the cartridge chamber of the box housing, so that when the box cap is locked and engaged with the box housing, the hollow needle tip is aligned with the central axis of each chamber and the cartridge axis thus installed.
[0024] The cartridge housing and cartridge cap are sized such that, when in locking engagement, each hollow needle tip pierces the septum of each cartridge mounted in a corresponding chamber of the cartridge housing.
[0025] Each hollow needle tip in the described hollow needle tip is communicated with the fluid channel fluid in the body of box cap. Each fluid channel in the described fluid channel combines at a single outlet port, and the outlet port is centrally located at the axis of the box housing assembly, and a flexible tubing is attached to the described box housing assembly. Therefore, the hollow needle tip, fluid channel and outlet port jointly define the fluid manifold from each cartridge to a single outlet port and tubing. In an embodiment, a one-way check valve can be incorporated into the fluid channel to prevent fluid from flowing backwards.
[0026] A cannula is connected to the proximal end of the tubing, the cannula being arranged for delivering the cartridge contents subcutaneously to the patient. In an embodiment, the tubing may incorporate a flexible coupling to enable the cartridge housing to rotate independently of the proximal end of the tubing, thereby preventing rotation and kinking of the tubing.
[0027] In embodiments, a two-chamber cartridge arrangement may be utilized which would enable the device to be used for both reconstitution and delivery of a drug product.
[0028] In an embodiment, the cartridge housing assembly may incorporate identification technologies including, but not limited to, technologies such as radio frequency identification (RFID), near field communication (NFC) optical bar codes, and quick response codes for reading by the drive unit for identification purposes.
[0029] In a second aspect of the present invention, a drive unit is provided, which defines a chamber for receiving a cartridge housing assembly according to the above description, the drive unit comprising: a center alignment spindle for receiving the cartridge housing assembly through a center orifice; a dividing device for precise incremental rotation of the cartridge housing assembly; a plunger drive device for displacing an installed cartridge stopper to provide forward motive force for expelling liquid drug stored in the cartridge through a fluid manifold to a needle cannula; an electrical power source; and a control device.
[0030] The drive unit further includes a hinged latching door for retaining the cartridge housing within the chamber, external user controls and indicators, and means for wearably attaching to a patient. The door defines an aperture that defines a path for flexible tubing from the interior of the drive unit to the patient.
[0031] In an embodiment, the drive unit may further include a wireless communication device that implements a wireless communication protocol, including but not limited to a personal area network transceiver (e.g., Bluetooth, BTLE, Zigbee), a wireless network protocol (e.g., IEEE 802.11x, known as Wifi), a cellular communication protocol (e.g., GSM, EDGE, 4G LTE). In an embodiment, the communication protocol can be used to transmit data, including but not limited to date, time, location of use, identification and serial number of the drug box, etc.
[0032] The device can be used in a hospital or clinical setting; however, it is envisioned that the patient uses the device in a home use setting. Due to the use of discrete cartridges, the possibility of sequential delivery of combination therapies and time-resolved dosing, for example, for therapeutic or safety reasons, is possible. In the future, biomarker-based dosing is possible as patient diagnostic time and supply chain sensitivity continue to improve. BRIEF DESCRIPTION OF THE DRAWINGS
[0033] Figure 1 -View of a standard 1.5mL cartridge
[0034] Figure 2 - Exploded view of the box
[0035] Figure 3 - Complete Ready to Use (RTU) Box
[0036] Figure 4 - Manifold top and perspective views
[0037] Figure 5 - View of the cassette with the top of the manifold attached
[0038] Figure 6 -Belt wear drive unit
[0039] Figure 7 - View of the drive unit UI and external features
[0040] Figure 8 -Box door button with interlock device
[0041] Fig. 9 - Cartridge rotation mechanism in the drive unit
[0042] Fig.10 -Box rotation mechanism parts
[0043] Fig.11 -Slewing mechanism operation
[0044] Fig.12 - Cross-sectional view of the drive unit components
[0045] Fig.13 - Plunger rod to expel the contents of the cartridge
[0046] Figure 14-17 -Alternative drive unit configurations DETAILED DESCRIPTION
[0047] Referring to the drawings, the drug combination will be delivered and configured by using a disposable box 10, which contains an arrangement of cartridges 1 filled with liquid drugs for sequential injection. As is known in the art, one or more of the cartridges can be dry / wet cartridges with separate dry and wet components, allowing dissolved or other powdered drugs to be reconstituted by a diluent within the cartridge (e.g., under the movement of the stopper 3). Figure 1 As shown, the cartridge 1 is a cylindrical glass tube, one end of which is formed to accommodate a crimped septum seal 2. Once the septum seal 2 is crimped onto the cartridge 1, the cartridge 1 is filled with a liquid drug product, and a plug 3 is inserted into the second open end to seal its contents. In order to dispense the fluid within the cartridge 1, the cannula 13 must first pierce the septum 2 to access the drug fluid chamber 4. With the fluid passage open, a force is applied to the plug 3, compressing the fluid held inside the cartridge 1, pushing it out of the cartridge 1 through the fluid passage of the cannula 13 traversing the septum 2.
[0048] like Figure 2As shown, the cassette 10 is used to contain a pre-configured arrangement of cartridges 1 and load them into a drive unit 20 for delivery to a patient. The cassette 10 is composed of the following components: a main body housing 5 having a holding chamber 7 for a plurality of cartridges 1 radially positioned about its lateral axis; and a housing top 6 that closes the cartridges 1 held in the main body housing 5, thereby capturing them within the main body housing 5. A cutout on the bottom of the main body housing 8 below each cartridge 1 allows physical access to the plug 3 within the cartridge 1, while a cutout 9 in the housing top 6 allows open access Figure 3 The cartridge septum 2 is shown. The box 10 is cylindrical in shape and is depicted as having a flat portion 11 on its outer surface, which is used to control its orientation when loaded into the drive unit 20. This unique shape is used as a keying feature and can take the form of different shapes or features in other embodiments. The box 10 depicted in the provided figures shows the use of seven discrete cartridges 1; if fewer cartridges are required, fewer cartridges can be assembled into the box 10, leaving an empty holding chamber 7. In embodiments where more cartridges are required, the box 10 can be designed to hold additional cartridges without limitation. An RFID tag or equivalent technology containing drug content and sequence information can be attached to the main body housing 5 to communicate with the drive unit 20 prior to delivery to ensure that a genuine and correct box 10 is being used.
[0049] like Figure 4 As shown, the cartridge manifold top 12 (which is a body having an interior cavity opposite to that of the cartridge housing top 6) is designed to fit over the cartridge housing top 6, over the cartridge septum 2, and be permanently locked to the cartridge 10 body. Figure 4 As shown, a sharp cannula 13 is located in the manifold top 12 above each cartridge 1, the sharp cannula is connected to a fluid channel 14 in the manifold top 12, the fluid channels all converge to a common output 15 at the axis of the manifold top 12. This common output 15 leads to an infusion set 16 with a needle 17, which will be inserted into the injection site in the patient's abdomen. When the manifold top 12 is mounted on the loaded cassette 10 ( Figure 5 ), each cannula 13 pierces its corresponding septum 2 and creates a fluid path from all cartridges 1 in the box 10 to the infusion set 16. In an embodiment, a check valve can be installed in line with each cannula 13 to correct backwash into other cartridges 1 during injection. During the manufacturing process, the cannula 13 with the manifold top 12 will be hermetically sealed, and the entire part with the infusion set 16 will undergo a terminal sterilization process, such as by using gamma radiation or ethylene oxide (EO).
[0050] When the drug product is held within the cartridge 10, it is delivered to the patient by means of the electromechanical belt wear drive unit 20. Figure 6 As shown, the drive unit 20 is attached to the patient by means of a belt or body strap 18; the cassette 10 is then loaded into the drive unit 20 while the infusion set 16 is free to exit from the drive unit 20. The infusion set 16 terminates in a 25G or similar needle 17 which is inserted into the patient's abdominal injection site.
[0051] exist Figure 7 An overview of the external features and controls of the drive unit 20 is depicted in FIG. On the front face of the drive unit 20, there is a cartridge door 19 that is spring biased to open automatically and is used to cover a cartridge receiving seat cylinder 28 within the drive unit 20. The cartridge door 19 has a cutout 21 to allow the infusion set 16 of the cartridge 10 to pass through the cartridge door 19 when closed. There is a mechanical button 22 on top of the drive unit 20 that the user presses to unlock the cartridge door 19 on the front face of the device to allow it to be opened. To prevent the user from opening the cartridge door 19 during operation, the cartridge door button 22 can be internally disabled by the device via a mechanical interlock 27 ( Figure 8 In addition, there is a simple user interface on top of the drive unit ( Figure 7 ), the user interface consists of a power button 25, a start / pause button 23, and a series of progressive LEDs 24. The user presses the power button 25 to power on or off the device, and the user presses the start / pause button 23 to start or pause the infusion process. The number of LEDs 24 present on the UI represents the number of cartridges 1 loaded into the device. As the device performs the infusion process, the LEDs 24 will light up to indicate that the cartridge 1 has completed its infusion. These controls and indicators on the top side are currently contained on a PCB mounted behind the outer housing of the drive unit 20. In an embodiment, these controls can be replaced by a touch display or remotely controlled by technologies such as Bluetooth. In an embodiment, a separate PCB mounted LED can be replaced by a single organic LED (oLED) display. On the rear face of the device is a USB C connector 26, which serves as a receiving seat for connecting a charger to recharge the internal battery 39 of the device.
[0052] The cartridge 10 is loaded into a cartridge barrel 28 which is shaped to receive the outer shape of the cartridge 10 so as to control the orientation of the cartridge 10 when loaded into the drive unit 20 ( Fig. 9 ). On the central axis of the cartridge barrel 28 is a spring loaded retainer 30 which is inserted into the central axis of the cartridge 10. When the cartridge 10 is pressed into the mechanism, the spring loaded tabs extend from the retainer 30, capturing the cartridge 10, locking it within the cartridge barrel 28 by its lateral axis. The cartridge barrel 28 and retainer 30 are attached to the rotating end of the rotator mechanism 29. In an embodiment, an RFID transmitter / receiver may be placed near the cartridge barrel 28 to identify and communicate with the loaded cartridge 10.
[0053] The rotator mechanism 29 (also referred to as an indexer) is configured to incrementally rotate the cassette 28 , in particular to align the cartridges 1 with the plunger rods 42 individually.
[0054] like Fig.10 As shown, the gyrator mechanism 29 includes a cylindrical carrier 31 having splines 32 and notches 33 cut radially into its inner wall. A drive shaft 34 extends into the carrier 31, where it terminates. This end of the drive shaft 34 is hollow, with its edges shaped as teeth 36. The outer surface of the drive shaft 34 within the carrier 31 is splined 35 for interfacing with the splines 32 of the carrier 31, thereby allowing the drive shaft 34 to move vertically only within the carrier 31. The drive shaft 34 is spring biased to push away from the carrier 31. A cartridge shaft 37 has a cartridge barrel 28 and a retaining mechanism 30 at one end, where the cartridge shaft 37 terminates within the carrier 31. This end of the cartridge shaft 37 that terminates within the carrier 31 has a ring of chamfered teeth 38 disposed around the shaft, which intersects with the notches 33 in the carrier 31, with the tip shaped to protrude into the hollow end of the drive shaft 34. The cartridge shaft 37 is rotatable within the carrier 31 and is spring biased toward the carrier 31. Fig.11 As shown in FIG. 1 , as the chamfered teeth 38 of the cartridge shaft 37 interface within the notch 33 of the carrier 31, an external force overcomes the spring bias of the drive shaft 34, pushing it into the carrier 31, thereby contacting the cartridge shaft 37. The teeth 36 at the end of the drive shaft 34 push the cartridge shaft 37 upward from the carrier 31, causing the chamfered teeth 38 of the cartridge shaft 37 to pass over the carrier notch 33. The teeth 36 of the drive shaft 34 then act as a ramp to guide the chamfered teeth 38 of the cartridge shaft 37 into the next notch 33 of the carrier 31. As the drive shaft 34 retracts to its starting position, the spring bias of the cartridge shaft 37 pushes the chamfered teeth 38 into the next notch 33 of the carrier 31, thereby rotating the cartridge shaft 37, and subsequently rotating the attached cartridge 10 by one notch. The number and geometry of the beveled teeth 38 on the drive shaft 37 and the carrier notches 33 control the resolution of the indexing steps and ensure axial alignment of the cartridge 1 within the cassette 10 with the plunger rod 42 of the drive unit 20 .
[0055] In an alternative embodiment, if Figures 14 to 17As shown, alternative means for rotating and aligning the box 10 can be considered, for example, a separate indexing drive motor 45 having a spur gear 46 that engages a toothed gear 47 integrally manufactured on the rear of the holder 30. The spur gear 46 is rotated by the drive motor 45 so that the gear 47 rotates with the box 10. The drive motor 45 can be reversible, thereby allowing bidirectional rotation adjustment of the box 10. The gear 47 is provided with one or more holes 48 through which the plunger rod 42 can pass to enter the aligned cartridge 1. In order to dispense the drug, the one or more holes 48 are aligned with the plunger rod 42, axially aligned with the aligned cartridge 1. Other arrangements are possible, such as a ratchet and pawl type mechanism.
[0056] An inclined surface 44 may be formed on the inner wall of the carrier 31 between the notches 33 to guide the beveled teeth 38 into the next notch 38 when rotating. Preferably, the inclined surface 44 is inclined downward in the desired rotation direction.
[0057] exist Fig.12 4 shows the internal components of the drive unit 20. The main components of the infusion drive system are the battery 39, the encoder motor 40, the drive train 41 and the plunger rod 42. During infusion, the encoder motor 40 is energized and will turn the drive train 41 to rotate the screw drive 43, thereby extending the plunger rod 42 forward from its initial position and extending into the cartridge barrel 28. The encoder motor 40 and custom firmware are used to track the position of the plunger rod 42. The firmware also has the ability to monitor the current of the encoder motor 40, which is directly related to the force applied by the plunger rod 42. When the plunger rod 42 enters the cartridge barrel 28, it passes through the main housing 5 of the cartridge via the plunger cutout 8 below each cartridge 1. The rotator mechanism 29 ensures that the plunger rod 42 will be axially aligned with the cartridge 10. Upon further travel, the plunger rod 42 then enters the cartridge 1, contacting the cartridge bung 3. The plunger rod 42 will continue to extend forward and will begin to drive the cartridge bung 3 into the cartridge 1 ( Fig.13), thereby expelling its contents into the cannula 13 piercing its septum 2, into the box top manifold 12, into the infusion kit 16 and into the patient. Once the contents of the cartridge 1 have been completely discharged, the encoder motor 40 will then be reversed to retract the plunger rod 42 to its initial position. When the initial position is reached, the plunger rod 42 will be further retracted beyond the initial position to interface with the drive shaft 34 of the gyrator mechanism 29. When the plunger rod 42 is further retracted, the drive shaft 34 of the gyrator mechanism 29 is driven into the carrier 31, causing the box barrel 28 to index a notch or cartridge position 1. Once the gyrator indexing is completed, the plunger rod 42 is reset to its initial position to repeat the process for the next box 1 in the box 10. In an embodiment, the rigid plunger rod 42 can be replaced with a flexible plunger rod or a telescopic plunger rod. Similarly, the device driving the plunger rod 42 can be replaced with a linear actuator, a pneumatic system, a magnetic system or a spring-based system.
[0058] As will be appreciated by those skilled in the art, the subject invention can be used to dose cartridges 1 in different sequences, including variations in full and partial dosing of cartridges 1. For example, the box 10 can be rotated to allow delivery in the order of cartridges 1, or one or more of the cartridges 1 can be skipped by additional rotations, allowing for later delivery. Moreover, the plunger rod 42 can be used to cause partial dosing of one or more cartridges 1, allowing return to permit further delivery from the same cartridge 1, thus allowing multiple dosing from one or more cartridges 1 in an established pattern. The flexibility of operation allows for the delivery of multiple drugs in different amounts and in different sequences, allowing for the delivery of different combinations in different situations.
[0059] In one embodiment, any combination drug delivery device disclosed herein can deliver two or more drugs to benefit patients suffering from any of a variety of diseases or conditions (e.g., cancer, autoimmune disorders, inflammatory disorders, cardiovascular diseases, or fibrotic disorders). In one embodiment, one or more cartridges in cartridge 1 can contain a single drug. In one embodiment, one or more cartridges in cartridge 1 can contain two or more co-formulated drugs. In one embodiment, one or more cartridges in cartridge 1 can contain a drug in solid form (such as tablets, capsules, powders, freeze-dried, spray-dried), which can be reconstructed by a diluent stream therein to form a liquid drug.
[0060] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is an immune checkpoint inhibitor. In certain embodiments, the immune checkpoint inhibitor is a programmed death-1 ("PD-1") pathway inhibitor, a cytotoxic T lymphocyte-associated antigen 4 ("CTLA-4") antagonist, a lymphocyte activation gene-3 ("LAG3") antagonist, a CD80 antagonist, a CD86 antagonist, a T cell immunoglobulin and mucin domain ("Tim-3") antagonist, a T cell immunoreceptor with Ig and ITIM domains ("TIGIT") antagonist, a CD20 antagonist, a CD96 antagonist, an indoleamine 2,3-dioxygenase ("IDO1") antagonist, a stimulator of interferon genes ("STING") antagonist, a GARP antagonist, a CD40 antagonist, an adenosine A2A receptor ("A2aR") antagonist, a CEACAM1 (CD66a) antagonist, a CEA antagonist, a CD47 antagonist, a receptor-associated immunoglobulin domain-containing protein (Receptor Related Immunoglobulin Domain Containing Protein, "PVRIG") antagonists, tryptophan 2,3-dioxygenase ("TDO") antagonists, V-domain Ig inhibitor of T cell activation ("VISTA") antagonists, or killer cell immunoglobulin-like receptor ("KIR") antagonists.
[0061] In one embodiment, the PD-1 pathway inhibitor is an anti-PD-1 antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-PD-1 antibody is pembrolizumab (KEYTRUDA; MK-3475), pidilizumab (CT-011), nivolumab (OPDIVO; BMS-936558), PDR001, MEDI0680 (AMP-514), TSR-042, REGN2810, JS001, AMP-224 (GSK-2661380), PF-06801591, BGB-A317, BI 754091 or SHR-1210.
[0062] In one embodiment, the PD-1 pathway inhibitor is an anti-PD-L1 antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-PD-L1 antibody is atezolizumab (TECENTRIQ; RG7446; MPDL3280A; RO5541267), durvalumab (MEDI4736), BMS-936559, avelumab (bavencio), LY3300054, CX-072 (Proclaim-CX-072), FAZ053, KN035, or MDX-1105.
[0063] In one embodiment, the PD-1 pathway inhibitor is a small molecule drug. In certain embodiments, the PD-1 pathway inhibitor is CA-170. In another embodiment, the PD-1 pathway inhibitor is a cell-based therapy. In one embodiment, the cell-based therapy is a PD-L1 / L2-silenced dendritic cell vaccine loaded with MiHA. In other embodiments, the cell-based therapy is an anti-programmed cell death protein 1 antibody expressing multipotent killer T lymphocytes, autologous PD-1 targeted chimeric conversion receptor-modified T lymphocytes, or PD-1 knocked-out autologous T lymphocytes.
[0064] In one embodiment, the PD-1 pathway inhibitor is an anti-PD-L2 antibody or an antigen-binding fragment thereof. In another embodiment, the anti-PD-L2 antibody is rHIgM12B7.
[0065] In one embodiment, the PD-1 pathway inhibitor is a soluble PD-1 polypeptide. In certain embodiments, the soluble PD-1 polypeptide is a fusion polypeptide. In some embodiments, the soluble PD-1 polypeptide comprises a ligand binding fragment of the PD-1 extracellular domain. In other embodiments, the soluble PD-1 polypeptide comprises a ligand binding fragment of the PD-1 extracellular domain. In another embodiment, the soluble PD-1 polypeptide further comprises an Fc domain.
[0066] In one embodiment, the immune checkpoint inhibitor is a CTLA-4 antagonist. In certain embodiments, the CTLA-4 antagonist is an anti-CTLA-4 antibody or an antigen-binding fragment thereof. In some embodiments, the anti-CTLA-4 antibody is ipilimumab (YERVOY), tremelimumab (tremelimumab) (ticilimumab; CP-675,206), AGEN-1884 or ATOR-1015. In one embodiment, any combination drug delivery device disclosed herein includes a CTLA-4 antagonist, such as ipilimumab (YERVOY); and a PD-1 pathway inhibitor, such as nivolumab (OPDIVO) or pembrolizumab (KEYTRUDA).
[0067] In one embodiment, the immune checkpoint inhibitor is an antagonist of LAG3. In certain embodiments, the LAG3 antagonist is an anti-LAG3 antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-LAG3 antibody is relatlimab (BMS-986016), MK-4280 (28G-10), REGN3767, GSK2831781, IMP731 (H5L7BW), BAP050, IMP-701 (LAG-5250), IMP321, TSR-033, LAG525, BI 754111 or FS-118. In one embodiment, any combination drug delivery device disclosed herein includes a LAG3 antagonist, such as relatlimab or MK-4280; and a PD-1 pathway inhibitor, such as nivolumab (OPDIVO) or pembrolizumab (KEYTRUDA). In one embodiment, any combination drug delivery device disclosed herein includes a LAG3 antagonist, such as relalizumab or MK-4280; and a CTLA-4 antagonist, such as ipilimumab (YERVOY). In one embodiment, any combination drug delivery device disclosed herein includes a LAG3 antagonist, such as relalizumab or MK-4280; a CTLA-4 antagonist, such as ipilimumab (YERVOY); and a PD-1 pathway inhibitor, such as nivolumab (OPDIVO) or pembrolizumab (KEYTRUDA).
[0068] In one embodiment, the immune checkpoint inhibitor is a KIR antagonist. In certain embodiments, the KIR antagonist is an anti-KIR antibody or an antigen-binding fragment thereof. In some embodiments, the anti-KIR antibody is lirilumab (1-7F9, BMS-986015, IPH 2101) or IPH4102.
[0069] In one embodiment, the immune checkpoint inhibitor is a TIGIT antagonist. In one embodiment, the TIGIT antagonist is an anti-TIGIT antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-TIGIT antibody is BMS-986207, AB 154, COM902 (CGEN-15137), or OMP-313M32.
[0070] In one embodiment, the immune checkpoint inhibitor is a Tim-3 antagonist. In certain embodiments, the Tim-3 antagonist is an anti-Tim-3 antibody or an antigen-binding fragment thereof. In some embodiments, the anti-Tim-3 antibody is TSR-022 or LY3321367.
[0071] In one embodiment, the immune checkpoint inhibitor is an IDO1 antagonist. In another embodiment, the IDO1 antagonist is indoximod (NLG8189; 1-methyl-D-TRP), icadolstat (INCB-024360, INCB-24360), KHK2455, PF-06840003, navoximod (RG6078, GDC-0919, NLG919), BMS-986205 (F001287) or a pyrrolidine-2,5-dione derivative.
[0072] In one embodiment, the immune checkpoint inhibitor is a STING antagonist. In certain embodiments, the STING antagonist is a 2' or 3'-monofluoro-substituted cyclic dinucleotide; a 2'3'-difluoro-substituted mixed-bond 2',5'–3',5' cyclic dinucleotide; a 2'-fluoro-substituted bis-3',5' cyclic dinucleotide; a 2',2"-diF-Rp,Rp,bis-3',5' cyclic dinucleotide; or a fluorinated cyclic dinucleotide.
[0073] In one embodiment, the immune checkpoint inhibitor is a CD20 antagonist. In some embodiments, the CD20 antagonist is an anti-CD20 antibody or an antigen-binding fragment thereof. In one embodiment, the anti-CD20 antibody is rituximab (RITUXAN; IDEC-102; IDEC-C2B8), ABP 798, ofatumumab or obinutuzumab.
[0074] In one embodiment, the immune checkpoint inhibitor is a CD80 antagonist. In certain embodiments, the CD80 antagonist is an anti-CD80 antibody or an antigen-binding fragment thereof. In one embodiment, the anti-CD80 antibody is galiximab or AV 1142742.
[0075] In one embodiment, the immune checkpoint inhibitor is a GARP antagonist. In some embodiments, the GARP antagonist is an anti-GARP antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-GARP antibody is ARGX-115.
[0076] In one embodiment, the immune checkpoint inhibitor is a CD40 antagonist. In certain embodiments, the CD40 antagonist is an anti-CD40 antibody or an antigen-binding fragment thereof. In some embodiments, the anti-CD40 antibody is BMS3h-56, lucatumumab (lucatumumab) (HCD122 and CHIR-12.12), CHIR-5.9 or dacetuzumab (dacetuzumab) (huS2C6, PRO 64553, RG 3636, SGN 14, SGN-40). In another embodiment, the CD40 antagonist is a soluble CD40 ligand (CD40-L). In one embodiment, the soluble CD40 ligand is a fusion polypeptide. In one embodiment, the soluble CD40 ligand is CD40-L / FC2 or a monomeric CD40-L.
[0077] In one embodiment, the immune checkpoint inhibitor is an A2aR antagonist. In some embodiments, the A2aR antagonist is a small molecule. In certain embodiments, the A2aR antagonist is CPI-444, PBF-509, istradefylline (KW-6002), preladenant (SCH420814), tozadenant (SYN115), vipadenant (BIIB014), HTL-1071, ST1535, SCH412348, SCH442416, SCH58261, ZM241385 or AZD4635.
[0078] In one embodiment, the immune checkpoint inhibitor is a CEACAM1 antagonist. In some embodiments, the CEACAM1 antagonist is an anti-CEACAM1 antibody or an antigen-binding fragment thereof. In one embodiment, the anti-CEACAM1 antibody is CM-24 (MK-6018).
[0079] In one embodiment, the immune checkpoint inhibitor is a CEA antagonist. In one embodiment, the CEA antagonist is an anti-CEA antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-CEA antibody is cergutuzumab amunaleukin (RG7813, RO-6895882) or RG7802 (RO6958688).
[0080] In one embodiment, the immune checkpoint inhibitor is a CD47 antagonist. In some embodiments, the CD47 antagonist is an anti-CD47 antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-CD47 antibody is HuF9-G4, CC-90002, TTI-621, ALX148, NI-1701, NI-1801, SRF231, or Effi-DEM.
[0081] In one embodiment, the immune checkpoint inhibitor is a PVRIG antagonist. In certain embodiments, the PVRIG antagonist is an anti-PVRIG antibody or an antigen-binding fragment thereof. In one embodiment, the anti-PVRIG antibody is COM701 (CGEN-15029).
[0082] In one embodiment, the immune checkpoint inhibitor is a TDO antagonist. In one embodiment, the TDO antagonist is a 4- (indol-3-yl) -pyrazole derivative, a 3- indole substituted derivative or a 3- (indol-3-yl) -pyridine derivative. In another embodiment, the immune checkpoint inhibitor is an IDO and TDO dual antagonist. In one embodiment, IDO and TDO dual antagonists are small molecules.
[0083] In one embodiment, the immune checkpoint inhibitor is a VISTA antagonist. In some embodiments, the VISTA antagonist is CA-170 or JNJ-61610588.
[0084] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is an immune checkpoint enhancer or stimulator.
[0085] In one embodiment, the immune checkpoint enhancer or stimulator is a CD28 agonist, a 4-1BB agonist, an OX40 agonist, a CD27 agonist, a CD80 agonist, a CD86 agonist, a CD40 agonist, an ICOS agonist, a CD70 agonist, or a GITR agonist.
[0086] In one embodiment, the immune checkpoint enhancer or stimulator is an OX40 agonist. In certain embodiments, the OX40 agonist is an anti-OX40 antibody or an antigen-binding fragment thereof. In some embodiments, the anti-OX40 antibody is tavolixizumab (MEDI-0562), pogalizumab (MOXR0916, RG7888), GSK3174998, ATOR-1015, MEDI-6383, MEDI-6469, BMS 986178, PF-04518600 or RG7888 (MOXR0916). In another embodiment, the OX40 agonist is a cell-based therapy. In certain embodiments, the OX40 agonist is a GINAKIT cell (T lymphocyte expressing iC9-GD2-CD28-OX40).
[0087] In one embodiment, the immune checkpoint enhancer or stimulator is a CD40 agonist. In some embodiments, the CD40 agonist is an anti-CD40 antibody or an antigen-binding fragment thereof. In one embodiment, the anti-CD40 antibody is ADC-1013 (JNJ-64457107), RG7876 (RO-7009789), HuCD40-M2, APX005M (EPI-0050) or Chi Lob 7 / 4. In another embodiment, the CD40 agonist is a soluble CD40 ligand (CD40-L). In one embodiment, the soluble CD40 ligand is a fusion polypeptide. In certain embodiments, the soluble CD40 ligand is a trimeric CD40-L
[0088] In one embodiment, the immune checkpoint enhancer or stimulator is a GITR agonist. In certain embodiments, the GITR agonist is an anti-GITR antibody or an antigen-binding fragment thereof. In one embodiment, the anti-GITR antibody is BMS-986156, TRX518, GWN323, INCAGN01876 or MEDI1873. In one embodiment, the GITR agonist is a soluble GITR ligand (GITRL). In some embodiments, the soluble GITR ligand is a fusion polypeptide. In another embodiment, the GITR agonist is a cell-based therapy. In one embodiment, the cell-based therapy is an autologous dendritic cell vaccine transfected with anti-CTLA4 mAbRNA / GITRL RNA or an autologous dendritic cell vaccine transfected with GITRL RNA.
[0089] In one embodiment, the immune checkpoint enhancer or stimulator is a 4-1BB agonist. In some embodiments, the 4-1BB agonist is an anti-4-1BB antibody or its antigen-binding fragment. In one embodiment, the anti-4-1BB antibody is urelumab or PF-05082566.
[0090] In one embodiment, the immune checkpoint enhancer or stimulator is a CD80 agonist or a CD86 agonist. In some embodiments, the CD80 agonist or CD86 agonist is a soluble CD80 or CD86 ligand (CTLA-4). In certain embodiments, the soluble CD80 or CD86 ligand is a fusion polypeptide. In one embodiment, the CD80 or CD86 ligand is CTLA4-Ig (CTLA4-IgG4m, RG2077 or RG1046) or abatacept (ORENCIA, BMS-188667). In other embodiments, the CD80 agonist or CD86 agonist is a cell-based therapy. In one embodiment, the cell-based therapy is MGN1601 (allogeneic renal cell carcinoma vaccine).
[0091] In one embodiment, the immune checkpoint enhancer or stimulator is a CD28 agonist. In some embodiments, the CD28 agonist is an anti-CD28 antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-CD28 antibody is TGN1412.
[0092] In one embodiment, the CD28 agonist is a cell-based therapy. In certain embodiments, the cell-based therapy is JCAR015 (anti-CD19-CD28-ζ modified CAR CD3+T lymphocytes); T lymphocytes expressing CD28CAR / CD137CAR; allogeneic CD4+ memory Th1-like T cells / microparticle-bound anti-CD3 / anti-CD28; autologous T lymphocytes KTE-C19 transduced by anti-CD 19 / CD28 / CD3ζCARγ retroviral vector; autologous T lymphocytes transduced by anti-CEA IgCD28T CR; allogeneic T lymphocytes transduced by anti-EGFRvIIICAR; expressing CD123CA Autologous T lymphocytes expressing CD171-specific CAR-CD28ζ-4-1-BB-EGFRt; Autologous T lymphocytes enriched for Tcm expressing CD19CAR-CD28-CD3ζ-EGFRt; Autologous PD-1-targeted chimeric switch receptor-modified T lymphocytes (chimera with CD28); Autologous PD-1-targeted chimeric switch receptor-modified T lymphocytes expressing CD19CAR-CD28-C T lymphocytes enriched in Tcm expressing D3ζ-EGFRt; T lymphocytes enriched in Tn / mem expressing CD19CAR-CD28-CD3ζ-EGFRt; allogeneic T lymphocytes expressing CD19CAR-CD28ζ-4-1BB; autologous T lymphocytes expressing CD19CAR-CD3ζ-4-1BB-CD28; T lymphocytes expressing CD28CAR / CD137CAR; autologous T lymphocytes primed by CD3 / CD28 co-stimulatory vaccine; or T lymphocytes expressing iC9-GD2-CD28-OX40.
[0093] In one embodiment, the immune checkpoint enhancer or stimulator is a CD27 agonist. In certain embodiments, the CD27 agonist is an anti-CD27 antibody or an antigen-binding fragment thereof. In one embodiment, the anti-CD27 antibody is varlilumab (CDX-1127).
[0094] In one embodiment, the immune checkpoint enhancer or stimulator is a CD70 agonist. In some embodiments, the CD70 agonist is an anti-CD70 antibody or an antigen-binding fragment thereof. In one embodiment, the anti-CD70 antibody is ARGX-110.
[0095] In one embodiment, the immune checkpoint enhancer or stimulator is an ICOS agonist. In certain embodiments, the ICOS agonist is an anti-ICOS antibody or an antigen-binding fragment thereof. In some embodiments, the anti-ICOS antibody is BMS986226, MEDI-570, GSK3359609 or JTX-2011. In other embodiments, the ICOS agonist is a soluble ICOS ligand. In some embodiments, the soluble ICOS ligand is a fusion polypeptide. In one embodiment, the soluble ICOS ligand is AMG 750.
[0096] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is an anti-CD73 antibody or an antigen-binding fragment thereof. In certain embodiments, the anti-CD73 antibody is MEDI9447.
[0097] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is a TLR9 agonist. In one embodiment, the TLR9 agonist is agatolimod sodium.
[0098] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein are cytokines. In certain embodiments, the cytokine is a member of the chemokine, interferon, interleukin, lymphokine, or tumor necrosis factor family. In some embodiments, the cytokine is IL-2, IL-15, or interferon-γ.
[0099] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein are TGF-β antagonists. In some embodiments, the TGF-β antagonist is fresolimumab (GC-1008); NIS793; IMC-TR1 (LY3022859); ISTH0036; trabedersen (AP 12009); recombinant transforming growth factor-β-2; autologous HPV-16 / 18E6 / E7-specific TGF-β-resistant T lymphocytes; or TGF-β-resistant LMP-specific cytotoxic T lymphocytes.
[0100] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is an iNOS antagonist. In some embodiments, the iNOS antagonist is N-acetylcysteine (NAC), aminoguanidine, L-nitroarginine methyl ester or S,S-1,4-phenylene-bis(1,2-ethanediyl)bis-isothiourea).
[0101] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is a SHP-1 antagonist.
[0102] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is a colony stimulating factor 1 receptor ("CSF1R") antagonist. In certain embodiments, the CSF1R antagonist is an anti-CSF1R antibody or an antigen-binding fragment thereof. In some embodiments, the anti-CSF1R antibody is emactuzumab.
[0103] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is an agonist of a TNF family member. In some embodiments, the agonist of a TNF family member is ATOR 1016, ABBV-621, or adalimumab.
[0104] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is interleukin 2 (IL-2), such as aldesleukin. Preferably, IL-2 or conjugated IL-2 (e.g., pegylated) has been modified to selectively activate T effector cells relative to T regulatory cells ("T-eff IL-2"), such as bempegaldesleukin. In one embodiment, any combination drug delivery device disclosed herein includes a modified IL-2 that selectively activates T effector cells relative to T regulatory cells, such as bempegaldesleukin; and a PD-1 pathway inhibitor, such as nivolumab (OPDIVO) or pembrolizumab (KEYTRUDA). In one embodiment, any combination drug delivery device disclosed herein includes a modified IL-2 that selectively activates T effector cells relative to T regulatory cells, such as bempegaldesleukin; and a LAG3 antagonist, such as relalizumab or MK-4280. In one embodiment, any combination drug delivery device disclosed herein includes a modified IL-2 that selectively activates T effector cells relative to T regulatory cells, such as bepealdeleukin; and a PD-1 pathway inhibitor, such as nivolumab (OPDIVO) or pembrolizumab (KEYTRUDA); and a LAG3 antagonist, such as relalizumab or MK-4280. In one embodiment, any combination drug delivery device disclosed herein includes a modified IL-2 that selectively activates T effector cells relative to T regulatory cells, such as bepealdeleukin; and a CTLA-4 antagonist, such as ipilimumab (YERVOY). In one embodiment, any combination drug delivery device disclosed herein includes a modified IL-2 that selectively activates T effector cells relative to T regulatory cells, such as bepealdeleukin; a PD-1 pathway inhibitor, such as nivolumab (OPDIVO) or pembrolizumab (KEYTRUDA); and a CTLA-4 antagonist, such as ipilimumab (YERVOY). In one embodiment, any combination drug delivery device disclosed herein includes a modified IL-2 that selectively activates T effector cells relative to T regulatory cells, such as benpei aldesleukin; a CTLA-4 antagonist, such as ipilimumab (YERVOY); and a LAG3 antagonist, such as relalizumab or MK-4280. In one embodiment, any combination drug delivery device disclosed herein includes a modified IL-2 that selectively activates T effector cells relative to T regulatory cells, such as benpei aldesleukin; a PD-1 pathway inhibitor, such as nivolumab (OPDIVO) or pembrolizumab (KEYTRUDA); a CTLA-4 antagonist, such as ipilimumab (YERVOY); and a LAG3 antagonist, such as relalizumab or MK-4280.
[0105] In one embodiment, one or more of the drugs of any combination drug delivery device disclosed herein is a CD160 (NK1) agonist. In certain embodiments, the CD160 (NK1) agonist is an anti-CD160 antibody or an antigen-binding fragment thereof. In one embodiment, the anti-CD160 antibody is BY55.
[0106] In one embodiment, one or more cartridges in cartridge 1 may include soluble CTLA-4 polypeptides, which can be used to treat, for example, T cell-mediated autoimmune disorders, such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, graft-versus-host disease, and transplant rejection. In one embodiment, the soluble CTLA-4 polypeptide is abatacept (ORENCIA), belatacept (NULOJIX), RG2077, or RG-1046. In certain embodiments, one or more cartridges in the cartridge 1 of a combined drug delivery device as described herein include soluble CTLA-4 polypeptides, such as abatacept (ORENCIA); and Bruton's tyrosine kinase inhibitors, such as branebrutinib. In certain embodiments, one or more cartridges in the cartridge 1 of a combined drug delivery device as described herein include soluble CTLA-4 polypeptides, such as abatacept (ORENCIA); and tyrosine kinase-2 inhibitors, such as BMS-986165. In certain embodiments, one or more cartridges in cartridge 1 of a combination drug delivery device as described herein include a soluble CTLA-4 polypeptide, such as abatacept (ORENCIA); and interleukin-2 (IL-2) or "T-reg IL-2" that selectively activates T regulatory cells as opposed to T effector cells, such as BMS-986326 and NKTR-358.
[0107] In summary, the present invention includes but is not limited to the following items:
[0108] 1. A drug delivery device for delivering a drug from a plurality of drug cartridges, each of the drug cartridges comprising an elongated body and a plug located in the body, the elongated body having a first end sealed with a septum and a second open end, the drug delivery device comprising:
[0109] a cylindrical case configured to house the plurality of drug cartridges;
[0110] A reversibly advanceable plunger; and
[0111] an indexer for incrementally rotating the cassette to individually align the plurality of drug cartridges with the plungers, the indexer comprising:
[0112] a first shaft coupled to the cartridge so as to rotate therewith; and
[0113] a second shaft coaxially aligned with the first shaft and normally biased to be spaced apart from the first shaft,
[0114] Wherein the second shaft is axially displaceable to engage the first shaft, and wherein the first shaft and the second shaft include cooperating elements that cause incremental rotation of the first shaft relative to the second shaft when the second shaft engages the first shaft.
[0115] 2. The drug delivery device of claim 1, further comprising a plurality of cannulas positioned to pierce the septa of the plurality of drug cartridges.
[0116] 3. The drug delivery device of claim 1, wherein the indexer further comprises a tubular carrier into which the first and second shafts extend.
[0117] 4. A drug delivery device according to claim 3, wherein the carrier includes a plurality of recesses defined on an inner surface thereof, wherein the first shaft includes a plurality of beveled teeth formed to intersect with the plurality of recesses, and wherein the first shaft is biased so that the beveled teeth intersect with the plurality of recesses in a normal state.
[0118] 5. A drug delivery device according to claim 4, wherein the second shaft includes a plurality of teeth, wherein when the second shaft is axially displaced relative to the first shaft, the plurality of teeth engage the plurality of beveled teeth to separate the plurality of beveled teeth from the plurality of notches.
[0119] 6. A drug delivery device according to clause 5, wherein the plurality of bevelled teeth are incrementally rotated and urged into engagement with the plurality of notches when the second shaft is returned to be spaced apart from the first shaft.
[0120] 7. The drug delivery device according to item 4, wherein the carrier includes a plurality of inclined surfaces defined on an inner surface thereof, the inclined surfaces being located between the plurality of recesses.
[0121] 8. A drug delivery device for delivering a drug from a plurality of drug cartridges, each of the drug cartridges comprising an elongated body and a plug located in the body, the elongated body having a first end sealed with a septum and a second open end, the drug delivery device comprising:
[0122] a cylindrical case configured to house the plurality of drug cartridges;
[0123] A plunger capable of reverse advancement;
[0124] Indexing drive motor;
[0125] a spur gear coupled to the indexing drive motor; and
[0126] a toothed gear coupled to the cartridge and engaged with the spur gear, one or more apertures being formed in the toothed gear, wherein as the spur gear is rotated by the indexing drive motor, the toothed gear is caused to rotate with the cartridge to individually align the plurality of drug cartridges with the plungers.
[0127] 9. A drug delivery device according to item 8, wherein the indexing drive motor is reversible.
[0128] 10. A drug delivery device according to clause 8, wherein the plunger enters the aligned drug cartridge through the one or more apertures.
Claims
1. A drug delivery device for delivering a drug to a patient from a plurality of drug cartridges, each of the drug cartridges comprising an elongated body having a first end sealed with a septum and a second open end and a plug located in the body, wherein in an initial state each of the drug cartridges comprises at least one drug contained in the body between the plug and its septum, the drug delivery device comprising: a cylindrical case configured to house the plurality of drug cartridges, the case being elongated to extend along a longitudinal axis, each of the plurality of drug cartridges being arranged in the case to be parallel to the longitudinal axis, the case being rotatable about the longitudinal axis; a plurality of cannulas positioned to simultaneously pierce the septa of the plurality of drug cartridges; a plurality of fluid channels individually connected to the plurality of cannulas, the plurality of fluid channels converging to a common outlet; a reversibly advanceable plunger, said plunger being movable along an axis parallel to said longitudinal axis of said cartridge; as well as an indexer for incrementally rotating the box about the longitudinal axis to individually align the plurality of drug cartridges with the plunger, the plunger being advanceable to push the stopper of the aligned drug cartridge toward the septum of the aligned drug cartridge to cause the at least one drug contained in the body of the aligned drug cartridge to be expelled through the cannula piercing the septum of the aligned drug cartridge.
2. The drug delivery device of claim 1, wherein the indexer comprises: a first shaft coupled to the cartridge so as to rotate therewith; as well as a second shaft coaxially aligned with the first shaft and normally biased to be spaced apart from the first shaft, Wherein the second shaft is axially displaceable to engage the first shaft, and wherein the first shaft and the second shaft include cooperating elements that cause incremental rotation of the first shaft relative to the second shaft when the second shaft engages the first shaft.
3. The drug delivery device of claim 2, wherein the indexer further comprises a tubular carrier into which the first and second shafts extend.
4. The drug delivery device of claim 3, wherein the carrier includes a plurality of recesses defined on an inner surface thereof, wherein the first shaft includes a plurality of beveled teeth formed to interface with the plurality of recesses, and wherein the first shaft is biased such that the beveled teeth interface with the plurality of recesses in a normal state.
5. The drug delivery device of claim 4, wherein the second shaft comprises a plurality of teeth, wherein the plurality of teeth engage the plurality of beveled teeth to disengage the plurality of beveled teeth from the plurality of notches when the second shaft is axially displaced relative to the first shaft. 6 . The drug delivery device of claim 5 , wherein the plurality of beveled teeth are incrementally rotated and urged into engagement with the plurality of notches when the second shaft is returned to be spaced apart from the first shaft. 7 . The drug delivery device of claim 4 , wherein the carrier includes a plurality of inclined surfaces defined on an inner surface thereof, the inclined surfaces being located between the plurality of recesses.
8. The drug delivery device of claim 1, wherein the indexer comprises an indexing drive motor and a spur gear coupled to the indexing drive motor.
9. The drug delivery device of claim 1, wherein the indexer comprises a ratchet and pawl mechanism.
